Know Cancer

forgot password

CSP #380 - Prospective Evaluation of Risk Factors for Large (> 1 CM) Colonic Adenomas in Asymptomatic Subjects

Phase 3
50 Years
75 Years
Not Enrolling
Colorectal Cancer

Thank you

Trial Information

CSP #380 - Prospective Evaluation of Risk Factors for Large (> 1 CM) Colonic Adenomas in Asymptomatic Subjects

Primary Hypothesis: Risk factors can be determined for large (>1 cm) adenomas, precursor
lesions for colorectal cancer.

Secondary Hypothesis: Determine long-term rates for development or recurrence of polyps;
determine sensitivity/specificity of current colon cancer screening strategies; determine
relationship of dietary factors and biomarkers of cell proliferation; determine the efficacy
and safety of long-term (5 years) repeat colonoscopy in patients with small polyps.

Intervention: Phase I: All patients undergo full colonoscopy. Phase II: Randomization to
repeat colonoscopy at 2-3 years and 5 years after baseline, or, repeat colonoscopy at 5
years only. Phase III: Ten-year follow-up on all Phase I patients for medical outcomes.
Repeat colonoscopy at 10 years on polyp-free patients (Phase I) aged 50-64.

Primary Outcomes: Presence of risk factors and adenomatous polyps including prevalence,
descriptive characteristics, and long-term occurrence/recurrence rates.

Study Abstract: Phase I is a cross-sectional study designed to identify risk factors for
large (>1 cm) adenomatous polyps. Approximately 3200 asymptomatic subjects (age 50-75) have
completed risk factor assessment, medical and dietary histories, and have undergone complete
colonoscopy examination. This will identify for comparison purposes a polyp-free control
group and is the first large prospective study to include such a group. Data at colonoscopy
will characterize the prevalence, size and distribution of adenomatous polyps. This will
permit an assessment of sensitivity of sigmoidoscopy in this population. In addition,
tissue from normal rectal mucosa will be analyzed for evidence of cell proliferation
activity. The primary focus of Phase I is a risk factor analysis. A multivariate analysis
will be performed to determine the relationship of historical and environmental factors as
well as cell proliferation activity with the presence of adenomatous polyps. A cohort
consisting of a subgroup of polyp patients (large and small) and matched polyp-free controls
will be tracked longitudinally to determine polyp occurrence/recurrence rates.

Phase II of the study is a long-term follow-up study designed to evaluate the relative risk
of two repeat colonoscopy schedules for patients with small polyps identified in Phase I of
the study. Recruitment is complete with 615 patients eligible (of the target 808) assigned
at random to either repeat colonoscopy at 2-3 years and 5 years, or to repeat colonoscopy at
5 years only. This phase will also provide preliminary longitudinal risk factor information
related to occurrence/recurrence of polyps.

Phase III was a 5-year extension of follow-up period. All Phase I patients were to be
reconsented to provide medical outcome data for a period of 10 years from baseline exam.
Phase I patients polyp-free, aged 50-64 will be offered repeat colonoscopy at 10 years to
evaluate long-term risk.

Results (Phase I): 3121 patients had complete colonoscopy which revealed high rates of
neoplasia: 37.5% had one or more neoplastic lesions; 10.5% had advanced neoplasia including
30 cases of invasive cancer (1%). There were 3.7% of patients with no lesions in the rectum
or sigmoid colon who had advanced neoplasia elsewhere in the colon: 32% of all patients with
advanced neoplasia would not be detected with an exam of the rectum or sigmoid colon
(distal); 62% of patients with proximal advanced neoplasia would not be detected with an
exam of the rectum and sigmoid colon. There were few serious complications (0.3%).

The one-time fecal occult blood test (FOBT) was evaluated as a diagnostic test for advanced
neoplasia. A positive FOBT indicated an increased likelihood (3-4x) of advanced neoplasia.
However, one-time FOBT failed to detect 75% of patients with advanced neoplasia.

The primary analysis of risk factors (Phase I) found positive associations (for advanced
neoplasia) for history of a first degree relative with colorectal cancer (OR, 1.66; 95% CI,
1.16-2.35), current smoking (OR, 1.85; 95% CI, 1.33-2.58), and current moderate to heavy
alcohol use (OR, 1.02, 95% CI, 1.01-1.03). Inverse associations were found for cereal fiber
intake (OR, 0.95, 95% CI, 0.91-0.99), vitamin D intake (OR, 0.94, 95% CI, 0.90-0.99), and
use of NSAIDs (OR, 0.66, 95% CI, 0.48-0.91). Results appeared in JAMA (2003;290:2959-2967).

Phase III is completed with patients completing their scheduled follow-ups. A major
manuscript on the sensitivity/specificity of digital rectal exam appeared in Annals of
Internal Medicine January, 2005. The Phase II results manuscript appeared in
Gastroenterology in October 2007.

Inclusion Criteria:

Study Complete

Exclusion Criteria:

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Outcome Measure:

Phase I: Risk factors include: family history; dietary; fat, fiber, calcium; alcohol history; tobacco use; physical activity; obesity; NSAID use; and, biomarkers: BRDU, PCNA

Outcome Time Frame:


Safety Issue:


Principal Investigator

David Lieberman, MD

Investigator Role:

Study Chair

Investigator Affiliation:

VA Medical Center, Portland


United States: Federal Government

Study ID:




Start Date:

October 1993

Completion Date:

February 2007

Related Keywords:

  • Colorectal Cancer
  • large (>1 cm) adenomas
  • Colorectal Neoplasms



VA Medical Center, Durham Durham, North Carolina  27705
Carl T. Hayden VA Medical Center Phoenix, Arizona  85012
VA Medical Center, Long Beach Long Beach, California  90822
Edward Hines, Jr. VA Hospital Hines, Illinois  60141-5000
VA Medical Center, San Francisco San Francisco, California  94121
VA Medical Center, Portland Portland, Oregon  97201
VA North Texas Health Care System, Dallas Dallas, Texas  75216
Southern Arizona VA Health Care System, Tucson Tucson, Arizona  85723
VA Medical Center, Kansas City MO Kansas City, Missouri  64128
VA Palo Alto Health Care System Palo Alto, California  94304-1207
VA Eastern Colorado Health Care System, Denver Denver, Colorado  80220
VA Medical Center, Minneapolis Minneapolis, Minnesota  55417
VA Medical & Regional Office Center, White River White River Junction, Vermont  05009-0001